In this paper, we addressed whether miR-21 ISH analysis in primary breast cancers can help to predict trastuzumab resistance in HER2-positive breast cancer patients treated with trastuzumab in the adjuvant setting, and whether the miR-21 expression pattern correlated with HER2 status or other known clinical markers. Here, ERBB2 is linked to breast carcinoma.